** Medical equipment maker Revvity's RVTY.N shares rise 8.2% to $102 premarket
** RVTY posts Q1 profit and revenue above Wall Street estimates and maintains its full-year profit forecast, helped by steady demand from biotech clients for medical equipment used for drug research
** Company posts a Q1 adj. profit of $1.01 per share, above analysts' estimates of 95 cents, according to data compiled by LSEG
** It reported Q1 revenue of $664.8 million, slightly above estimates of $661.2 million
** Company maintains annual profit forecast of $4.90 to $5 per share on an adjusted basis
** RVTY now sees 2025 revenue to be between $2.83 billion and $2.87 billion, compared with the previous projection of $2.80 billion to $2.85 billion
** Up to last close, stock had fallen 15.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.